Welcome to our dedicated page for Elanco Animal Health SEC filings (Ticker: ELAN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking how Elanco Animal Health turns veterinary science into revenue isn鈥檛 easy鈥攅ach 10-K details dozens of R&D pipeline assets, FDA approvals, and integration costs from the Bayer Animal Health acquisition. If you have ever asked, 鈥淲here can I read Elanco鈥檚 quarterly earnings report 10-Q filing?鈥� or 鈥淗ow do I locate Elanco insider trading Form 4 transactions?鈥� you already know the challenge.
Stock Titan solves it. Our AI-powered summaries translate the technical language in every Elanco SEC document into plain English, flagging segment margins, companion-animal growth, and farm-animal productivity trends. Receive real-time alerts the moment an Elanco Form 4 insider transactions real-time filing hits EDGAR, or open an Elanco 8-K material events explained card to see if a new parasiticide received FDA approval鈥攁ll without wading through hundreds of pages.
Here鈥檚 what you can explore in seconds:
- Elanco annual report 10-K simplified鈥擜I highlights pipeline updates, manufacturing efficiencies, and acquisition synergies.
- Elanco quarterly earnings report 10-Q filing鈥攃ompare sequential companion-animal sales and R&D spend.
- Elanco proxy statement executive compensation鈥攕ee how leadership incentives align with product launch milestones.
- Elanco executive stock transactions Form 4鈥攎onitor insider buying ahead of material announcements.
Whether you search 鈥渦nderstanding Elanco SEC documents with AI鈥� or need fast Elanco earnings report filing analysis, our platform keeps every filing type in one place, updated the moment Elanco submits it. Save hours, spot trends early, and make better calls on ELAN.
Elanco (ELAN) Q2 2025 10-Q highlights:
- Revenue rose 4.8% YoY to $1.24 bn; pet-health up 11% to $643 m, offsetting the divested aqua unit (zero vs $49 m).
- Gross margin held at 57.4% (713 m/1,241 m).
- Operating profile: SG&A climbed 13% to $400 m; R&D up 3% to $92 m; special charges plunged to $1 m from $80 m, driving a swing to positive pretax income of $25 m (-$32 m LY).
- Net income $11 m vs -$50 m; diluted EPS $0.02 vs -$0.10.
- Six-month totals: revenue +1.9% to $2.43 bn; net income $78 m vs -$18 m.
- Cash flow: operating cash +15% to $233 m; FCF negative as capex doubled to $122 m (new HQ).
- Balance sheet: cash $539 m (+$71 m YTD); total debt trimmed to $3.95 bn (ex-lease) from $4.32 bn; however a new $255 m finance lease and $293 m liability tied to royalty sale raise fixed commitments.
- Inventory up 6% YoY to $1.67 bn; accounts receivable +23%.
- Leverage: ~4.1脳 EBITDA remains high but 89% of debt is fixed; interest expense down 26% YoY.
- Strategic moves: 鈥� Closed $295 m royalty monetization with Blackstone (16.1% implied IRR). 鈥� HQ lease in Indianapolis (option to buy at $250 m in 2030). 鈥� Continued rollout of Zenrelia, Credelio Quattro, Bovaer; EU Zenrelia approval in Jul-25.
- Guidance not updated in filing.
Key takeaways: Return to profitability aided by lower one-offs and interest expense; pet-health momentum strong. Balance-sheet de-risking continues, but inventory build, rising SG&A and new fixed obligations temper the improvement.
FAQ
What is the current stock price of Elanco Animal Health (ELAN)?
What is the market cap of Elanco Animal Health (ELAN)?
